Chang Jun
Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea.
Immune Netw. 2021 Feb 15;21(1):e6. doi: 10.4110/in.2021.21.e6. eCollection 2021 Feb.
Adenovirus was originally used as a vector for gene therapy. In recent years, with the development of the next-generation vectors with increased safety and high immunogenicity to transgene products, its utility as a vaccine vector has continued to increase. Adenovirus-based vaccines are currently being tested not only to prevent various infectious diseases but also to be applied as cancer vaccines. In this review, I discuss the innate and adaptive aspects of the immunological characteristics of adenovirus vectors and further examine the current status of advanced adenovirus-based vaccine development. Various methods that can overcome the limitations of currently used adenoviruses as vaccine vehicles are also discussed. Through this study, I hope that vaccine development using adenovirus vectors will be expedited and more successful.
腺病毒最初被用作基因治疗的载体。近年来，随着安全性更高且对转基因产物免疫原性更强的下一代载体的发展，其作为疫苗载体的效用持续增加。目前，基于腺病毒的疫苗不仅正在进行预防各种传染病的测试，还被用作癌症疫苗进行试验。在这篇综述中，我将讨论腺病毒载体免疫特性的固有和适应性方面，并进一步审视基于腺病毒的先进疫苗开发的现状。还将讨论各种能够克服当前用作疫苗载体的腺病毒局限性的方法。通过这项研究，我希望利用腺病毒载体的疫苗开发能够加速并取得更大成功。
